Pub Date : 2026-02-06DOI: 10.1016/j.jconrel.2026.114696
Yuxuan Ge , Fan Rong , Zixin Wang , Yujia Lu , Yanwen Zhang , Yijun Cheng , Junsheng Chen , Yin Wang
Gouty arthritis (GA) is a common arthritis characterized by chronic inflammation and monosodium urate (MSU) crystal deposition in articular structures. Current clinical medications mainly target to alleviate the inflammation, but do less to the deposited MSU. Although administration of urate oxidase (UOx) could degrade the MSU, the toxic by-product hydrogen peroxide (H2O2) generated during the degradation would aggravate the inflammation. To surmount this, we developed a smart stimuli-responsive drug delivery platform (termed UBC) for the treatment of acute GA, where urate oxidase (UOx) was initially modified with the phenylboronic acid-based self-immolative thiocarbamate through nucleophilic substitution, and then co-assembled with curcumin through boronate bonds. This way, the platform could not only directly eliminate MSU, but also release the therapeutic agents, hydrogen sulfide (H2S) gas and curcumin, triggered by the toxic by-product H2O2 during UOx catalysis. Thus, the inflammation could be effectively restrained by the in situ co-delivery of H2S and curcumin. We believe this strategy provides a novel approach for the treatment of inflammation-related diseases and novel insight into the construction of multi-functional therapeutic nanomaterials from enzymes or other biomolecules.
{"title":"Curcumin driven formation of self-cascade nanoclusters from urate oxidase-H2S donor conjugates for acute gouty arthritis alleviation","authors":"Yuxuan Ge , Fan Rong , Zixin Wang , Yujia Lu , Yanwen Zhang , Yijun Cheng , Junsheng Chen , Yin Wang","doi":"10.1016/j.jconrel.2026.114696","DOIUrl":"10.1016/j.jconrel.2026.114696","url":null,"abstract":"<div><div>Gouty arthritis (GA) is a common arthritis characterized by chronic inflammation and monosodium urate (MSU) crystal deposition in articular structures. Current clinical medications mainly target to alleviate the inflammation, but do less to the deposited MSU. Although administration of urate oxidase (UOx) could degrade the MSU, the toxic by-product hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) generated during the degradation would aggravate the inflammation. To surmount this, we developed a smart stimuli-responsive drug delivery platform (termed UBC) for the treatment of acute GA, where urate oxidase (UOx) was initially modified with the phenylboronic acid-based self-immolative thiocarbamate through nucleophilic substitution, and then co-assembled with curcumin through boronate bonds. This way, the platform could not only directly eliminate MSU, but also release the therapeutic agents, hydrogen sulfide (H<sub>2</sub>S) gas and curcumin, triggered by the toxic by-product H<sub>2</sub>O<sub>2</sub> during UOx catalysis. Thus, the inflammation could be effectively restrained by the <em>in situ</em> co-delivery of H<sub>2</sub>S and curcumin. We believe this strategy provides a novel approach for the treatment of inflammation-related diseases and novel insight into the construction of multi-functional therapeutic nanomaterials from enzymes or other biomolecules.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114696"},"PeriodicalIF":11.5,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146134060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1016/j.jconrel.2026.114690
Lei Xu , Zhuoshan Huang , Wenyue Zhang , Yuan Cao , Xiaotang Guo , Bo Hu , Rong Li , Qiusheng Lan , Xiaoding Xu
Activation of cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-interferon gene stimulator (STING) pathway has demonstrated significant potential in cancer treatment due to its crucial role in bridging the innate and adaptive immunity. However, clinical attempts of current cGAS-STING activating approaches remain challenged because of their undesired adverse effects and low therapeutic efficacy. We herein developed a new and robust immunostimulatory RNA interfering (RNAi) nanoplatform to potentiate breast cancer (BCa) immunotherapy through precise activation of cGAS-STING pathway and effective immune checkpoint blockade. This nanoplatform comprises the electrostatic complexes of small interfering RNA (siRNA) targeting oncogene coactivator-associated arginine methyltransferase 1 (Carm1) and metformin prodrug. Using orthotopic and metastatic BCa tumors, we demonstrated this nanoplatform could suppress the proliferation of BCa cells via siRNA-mediated Carm1 silencing and down-regulate programmed death-ligand 1 (PD-L1) expression via metformin-mediated ubiquitin-proteasome degradation. More importantly, due to the important role of oncogene Carm1 in repairing damaged double stand DNA (dsDNA), Carm1 silencing could specifically enhance the accumulation of damaged dsDNA and cytosolic release of dsDNA fragments to precisely activate the cGAS-STING pathway in BCa cells, which could thus promote their expression and secretion of interferon-β (IFN-β) to induce a significant inhibition of BCa tumor growth via leveraging both the innate and adaptive immunity.
{"title":"A robust RNAi nanoplatform for precise activation of cGAS-STING pathway and effective immune checkpoint blockade to potentiate cancer immunotherapy","authors":"Lei Xu , Zhuoshan Huang , Wenyue Zhang , Yuan Cao , Xiaotang Guo , Bo Hu , Rong Li , Qiusheng Lan , Xiaoding Xu","doi":"10.1016/j.jconrel.2026.114690","DOIUrl":"10.1016/j.jconrel.2026.114690","url":null,"abstract":"<div><div>Activation of cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-interferon gene stimulator (STING) pathway has demonstrated significant potential in cancer treatment due to its crucial role in bridging the innate and adaptive immunity. However, clinical attempts of current cGAS-STING activating approaches remain challenged because of their undesired adverse effects and low therapeutic efficacy. We herein developed a new and robust immunostimulatory RNA interfering (RNAi) nanoplatform to potentiate breast cancer (BCa) immunotherapy through precise activation of cGAS-STING pathway and effective immune checkpoint blockade. This nanoplatform comprises the electrostatic complexes of small interfering RNA (siRNA) targeting oncogene coactivator-associated arginine methyltransferase 1 (Carm1) and metformin prodrug. Using orthotopic and metastatic BCa tumors, we demonstrated this nanoplatform could suppress the proliferation of BCa cells via siRNA-mediated Carm1 silencing and down-regulate programmed death-ligand 1 (PD-L1) expression via metformin-mediated ubiquitin-proteasome degradation. More importantly, due to the important role of oncogene Carm1 in repairing damaged double stand DNA (dsDNA), Carm1 silencing could specifically enhance the accumulation of damaged dsDNA and cytosolic release of dsDNA fragments to precisely activate the cGAS-STING pathway in BCa cells, which could thus promote their expression and secretion of interferon-β (IFN-β) to induce a significant inhibition of BCa tumor growth via leveraging both the innate and adaptive immunity.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114690"},"PeriodicalIF":11.5,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146134066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1016/j.jconrel.2026.114686
Xingzi He , Yaping Li , Zhihui Xiang , Yifan Wu , Jinfeng Zhou , Peng Tang , Xiaoxiao Ji , Zhongming Huang , Jianbin Xu , Wei Wang , Yiying Qi
Osteomyelitis remains a formidable clinical challenge due to biofilm-associated antibiotic resistance, a hypoxic and immunosuppressive microenvironment, and progressive inflammatory bone destruction. To address these multifactorial barriers, we developed an ultrasound (US)-activatable injectable hydrogel, designated MIL-101(Fe)@ZnO@MM + PFO + Gel, which integrates sonodynamic catalysis, oxygen regulation, and immunomodulation within a single therapeutic platform. The core–shell nanostructure comprises MIL-101(Fe)@ZnO nanoflowers, synthesized via a seed-mediated growth process to couple the redox activity of iron with the peroxidase-like catalytic properties of ZnO. The core–shell nanostructure comprises MIL-101(Fe)@ZnO nanoflowers, synthesized via a seed-mediated growth process to couple the redox activity of iron with the peroxidase-like catalytic properties of ZnO. These nanozymes are camouflaged with a thiolated macrophage membrane (MM), dispersed in oxygen-enriched perfluorocarbon (PFO), and crosslinked within a quaternary ammonium-modified hydrogel matrix possessing biofilm-penetrating capability. Upon US irradiation, the hydrogel achieves deep biofilm penetration and generates abundant reactive oxygen species (ROS) through Fe/Zn synergistic catalysis, while PFO liquefaction releases oxygen to alleviate local hypoxia and potentiate the sonodynamic effect. In a rat model of methicillin-resistant Staphylococcus aureus (MRSA)-induced tibial osteomyelitis, this treatment markedly reduced bacterial load, substantially suppressed inflammatory infiltration and pro-inflammatory cytokine cascades, and effective mitigation of bone erosion. Collectively, MIL-101(Fe)@ZnO@MM + PFO + Gel+US offers a minimally invasive, spatiotemporally controlled platform for eradicating refractory infections and reprogramming the osteomyelitic microenvironment toward regeneration.
{"title":"Sonocatalytic multifunctional hydrogel in-situ remodels the infectious microenvironment for eradicating refractory osteomyelitis","authors":"Xingzi He , Yaping Li , Zhihui Xiang , Yifan Wu , Jinfeng Zhou , Peng Tang , Xiaoxiao Ji , Zhongming Huang , Jianbin Xu , Wei Wang , Yiying Qi","doi":"10.1016/j.jconrel.2026.114686","DOIUrl":"10.1016/j.jconrel.2026.114686","url":null,"abstract":"<div><div>Osteomyelitis remains a formidable clinical challenge due to biofilm-associated antibiotic resistance, a hypoxic and immunosuppressive microenvironment, and progressive inflammatory bone destruction. To address these multifactorial barriers, we developed an ultrasound (US)-activatable injectable hydrogel, designated MIL-101(Fe)@ZnO@MM + PFO + Gel, which integrates sonodynamic catalysis, oxygen regulation, and immunomodulation within a single therapeutic platform. The core–shell nanostructure comprises MIL-101(Fe)@ZnO nanoflowers, synthesized via a seed-mediated growth process to couple the redox activity of iron with the peroxidase-like catalytic properties of ZnO. The core–shell nanostructure comprises MIL-101(Fe)@ZnO nanoflowers, synthesized via a seed-mediated growth process to couple the redox activity of iron with the peroxidase-like catalytic properties of ZnO. These nanozymes are camouflaged with a thiolated macrophage membrane (MM), dispersed in oxygen-enriched perfluorocarbon (PFO), and crosslinked within a quaternary ammonium-modified hydrogel matrix possessing biofilm-penetrating capability. Upon US irradiation, the hydrogel achieves deep biofilm penetration and generates abundant reactive oxygen species (ROS) through Fe/Zn synergistic catalysis, while PFO liquefaction releases oxygen to alleviate local hypoxia and potentiate the sonodynamic effect. In a rat model of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-induced tibial osteomyelitis, this treatment markedly reduced bacterial load, substantially suppressed inflammatory infiltration and pro-inflammatory cytokine cascades, and effective mitigation of bone erosion. Collectively, MIL-101(Fe)@ZnO@MM + PFO + Gel+US offers a minimally invasive, spatiotemporally controlled platform for eradicating refractory infections and reprogramming the osteomyelitic microenvironment toward regeneration.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114686"},"PeriodicalIF":11.5,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146134055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1016/j.jconrel.2026.114703
Enhao Lu , Xueli Huang , Qi Zhang , Kuankuan Luo , Xin Yan , Weimin Nie , Lingmin Zhang , Ruining Hu , Jing Bian , Yue Li , Yu Luo , Zhiwen Zhang , Jing Zhao , Xianyi Sha
Peripheral neuropathy and microcirculation distribution are key causes of diabetic foot ulcers (DFUs). Based on the vessel dilation and nerve regeneration effect of nitric oxide (NO), a multi-functional nanoparticles-hydrogel therapy system was developed in this research. In order to inhibit the side effect of NO which could form peroxynitrite anions (ONOO−) and lead to cytotoxicity, dual strategies were purposed, including physiologic NO generation and combination therapy with anti-oxidation. This kind of in situ NO generation was also proved to accelerate the permeation of nanoparticles, mainly by changes of tissue structures or functions. The solid lipid nanoparticles (SLNs) were prepared by microfluidic method, considering the poor stability of both arginine modified cholesterol (Chol-Arg) and reduced coenzyme Q10 that were used in prescription. These Q10/NO-SLNs were then encapsulated in an anti-bacterial and glucose sensitive ε-polylysine (EPL) based hydrogel. The multiple bio-functions of Q10/NO-SLN@EPLgel system were investigated and proved thoroughly both in vitro and in vivo, including +677.8% wound healing rate, +670.0% nanoparticle permeation, +312.5% blood supply in wound area, and + 229.3% neuron density in wound sections. In conclusion, Q10/NO-SLN@EPLgel was proved to be an effective DFUs wound dressing, and promoting nerve regeneration should be considered vital in therapy of DFUs.
周围神经病变和微循环分布是糖尿病足溃疡(DFUs)的主要原因。基于一氧化氮(NO)的血管扩张和神经再生作用,本研究开发了一种多功能纳米颗粒-水凝胶治疗系统。为了抑制NO产生过氧亚硝酸盐阴离子(ONOO−)并导致细胞毒性的副作用,我们采用了生理性NO生成和抗氧化联合治疗的双重策略。这种原位NO生成也被证明加速了纳米颗粒的渗透,主要是通过改变组织结构或功能来实现的。针对处方中使用的精氨酸修饰胆固醇(cholr - arg)和还原性辅酶Q10稳定性较差的问题,采用微流控法制备了固体脂质纳米颗粒(SLNs)。然后将这些Q10/ no - sln包裹在抗菌和葡萄糖敏感的ε-聚赖氨酸(EPL)水凝胶中。Q10/NO-SLN@EPLgel体系具有+677.8%的创面愈合率、+670.0%的纳米颗粒通透性、+312.5%的创面血供、+ + 229.3%的创面神经元密度等多种生物功能。综上所述,Q10/NO-SLN@EPLgel是一种有效的DFUs创面敷料,促进神经再生在DFUs治疗中应被视为至关重要。
{"title":"A precision nitric oxide-releasing hydrogel promoting nanoparticles permeation for comprehensive nerve-vessel recovery and microenvironment regulation in diabetic wounds","authors":"Enhao Lu , Xueli Huang , Qi Zhang , Kuankuan Luo , Xin Yan , Weimin Nie , Lingmin Zhang , Ruining Hu , Jing Bian , Yue Li , Yu Luo , Zhiwen Zhang , Jing Zhao , Xianyi Sha","doi":"10.1016/j.jconrel.2026.114703","DOIUrl":"10.1016/j.jconrel.2026.114703","url":null,"abstract":"<div><div>Peripheral neuropathy and microcirculation distribution are key causes of diabetic foot ulcers (DFUs). Based on the vessel dilation and nerve regeneration effect of nitric oxide (NO), a multi-functional nanoparticles-hydrogel therapy system was developed in this research. In order to inhibit the side effect of NO which could form peroxynitrite anions (ONOO<sup>−</sup>) and lead to cytotoxicity, dual strategies were purposed, including physiologic NO generation and combination therapy with anti-oxidation. This kind of in situ NO generation was also proved to accelerate the permeation of nanoparticles, mainly by changes of tissue structures or functions. The solid lipid nanoparticles (SLNs) were prepared by microfluidic method, considering the poor stability of both arginine modified cholesterol (Chol-Arg) and reduced coenzyme Q<sub>10</sub> that were used in prescription. These Q<sub>10</sub>/NO-SLNs were then encapsulated in an anti-bacterial and glucose sensitive ε-polylysine (EPL) based hydrogel. The multiple bio-functions of Q<sub>10</sub>/NO-SLN@EPL<sup>gel</sup> system were investigated and proved thoroughly both in vitro and in vivo, including +677.8% wound healing rate, +670.0% nanoparticle permeation, +312.5% blood supply in wound area, and + 229.3% neuron density in wound sections. In conclusion, Q<sub>10</sub>/NO-SLN@EPL<sup>gel</sup> was proved to be an effective DFUs wound dressing, and promoting nerve regeneration should be considered vital in therapy of DFUs.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114703"},"PeriodicalIF":11.5,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146129459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1016/j.jconrel.2026.114694
Lei Cao (1) , Li Ren (1) , Longlin Yin (1) , Ping Xie , Guangyin Qiu , Tao Lu , Xueqing Huang , Wenhao Li , Wencheng Wu , Kun Zhang , Shi Zhou
Conventional transarterial chemoembolization (TACE) regimens for hepatocellular carcinoma (HCC) are often compromised in efficacy due to hypoxia and acidosis within the tumor microenvironment (TME), frequently leading to unsatisfactory treatment outcomes and tumor recurrence. To overcome these limitations, this study introduces an innovative approach by incorporating a hydrogen generator (calcium hydride, CaH₂) into an epirubicin (EPI)–iodized oil embolization system. This design enables local hydrogen release to remodel the TME following TACE, thereby enhancing the combined chemo-immunotherapeutic antitumor response. Nano-CaH₂ particles, co-delivered locally via TACE, undergo hydrolysis to continuously release hydrogen gas (H₂) and calcium ions (Ca2+). This reaction disrupts mitochondrial function in cancer cells, reduces oxygen consumption, alleviates tumor hypoxia, and consequently counteracts chemoresistance. Simultaneously, EPI induces immunogenic cell death (ICD) in moribund tumor cells, activating the host's antitumor immune response. Additionally, the hydroxide ions generated from CaH₂ hydrolysis neutralize the acidic TME, alleviating immunosuppression and further amplifying the chemo-immunotherapeutic synergy mediated by TACE. This strategy presents a novel method to improve TACE efficacy and facilitate its integration with immunotherapy, demonstrating considerable potential for clinical translation.
{"title":"A hydrogen generator enhances immunogenic transarterial chemoembolization in hepatocellular carcinoma","authors":"Lei Cao (1) , Li Ren (1) , Longlin Yin (1) , Ping Xie , Guangyin Qiu , Tao Lu , Xueqing Huang , Wenhao Li , Wencheng Wu , Kun Zhang , Shi Zhou","doi":"10.1016/j.jconrel.2026.114694","DOIUrl":"10.1016/j.jconrel.2026.114694","url":null,"abstract":"<div><div>Conventional transarterial chemoembolization (TACE) regimens for hepatocellular carcinoma (HCC) are often compromised in efficacy due to hypoxia and acidosis within the tumor microenvironment (TME), frequently leading to unsatisfactory treatment outcomes and tumor recurrence. To overcome these limitations, this study introduces an innovative approach by incorporating a hydrogen generator (calcium hydride, CaH₂) into an epirubicin (EPI)–iodized oil embolization system. This design enables local hydrogen release to remodel the TME following TACE, thereby enhancing the combined chemo-immunotherapeutic antitumor response. Nano-CaH₂ particles, co-delivered locally via TACE, undergo hydrolysis to continuously release hydrogen gas (H₂) and calcium ions (Ca<sup>2+</sup>). This reaction disrupts mitochondrial function in cancer cells, reduces oxygen consumption, alleviates tumor hypoxia, and consequently counteracts chemoresistance. Simultaneously, EPI induces immunogenic cell death (ICD) in moribund tumor cells, activating the host's antitumor immune response. Additionally, the hydroxide ions generated from CaH₂ hydrolysis neutralize the acidic TME, alleviating immunosuppression and further amplifying the chemo-immunotherapeutic synergy mediated by TACE. This strategy presents a novel method to improve TACE efficacy and facilitate its integration with immunotherapy, demonstrating considerable potential for clinical translation.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114694"},"PeriodicalIF":11.5,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146134059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-05DOI: 10.1016/j.jconrel.2026.114689
Wenyu Zhang , Changshun Huang , Chengzhilin Li , Xinyu Wang , Ying Qu , Wenlong Duan , Yingyu Hou , Yingchun Zhao , Qingbin He , Jianwei Jiao , Zhengwei Liu , Runxiao Zheng
Pyroptosis, a unique type of inflammatory programmed cell death, has recently been identified as a promising therapeutic target for activating the immune system. Nevertheless, the effectiveness of pyroptosis in tumor immunotherapy is impeded by critical factors such as the failure to address nuclear factor-κB (NF-κB) priming, insufficient inflammasome activation, and limited light and oxygen penetration. To confront these challenges, we constructed crystalline dendritic mesoporous gadolinium oxide (DM-Gd2O3 nanoparticles) loaded with a peroxyoxalate-based chemiluminescence system and encapsulated by calcium carbonate (CaCO3) nanoparticles to form self-amplifying pyroptosis nanoinducers. Within the tumor microenvironment (TME), the release of pH-responsive calcium (Ca2+) and gadolinium ions (Gd3+) promotes the priming of NF-κB and disrupts lysosomal membrane phosphate groups, thereby inducing lysosomal rupture. Additionally, bis(3,4,6-trichloro-2-(pentyloxycarbonyl) phenyl) oxalate (CPPO) reacts with hydrogen peroxide (H2O2) to form a high-energy intermediate that emits light, exciting chlorin e6 (Ce6) to produce singlet oxygen. This process overcomes the limitations of light penetration and tumor hypoxia, synergizes with pyroptosis, and triggers a strong antitumor immune response in vitro and in vivo. This study introduces a novel approach to the design of self-amplifying pyroptosis nanoinducers for tumor immunotherapy.
{"title":"Self-amplifying pyroptosis nanoinducers enhance cancer immunotherapy through inflammasome priming and activation","authors":"Wenyu Zhang , Changshun Huang , Chengzhilin Li , Xinyu Wang , Ying Qu , Wenlong Duan , Yingyu Hou , Yingchun Zhao , Qingbin He , Jianwei Jiao , Zhengwei Liu , Runxiao Zheng","doi":"10.1016/j.jconrel.2026.114689","DOIUrl":"10.1016/j.jconrel.2026.114689","url":null,"abstract":"<div><div>Pyroptosis, a unique type of inflammatory programmed cell death, has recently been identified as a promising therapeutic target for activating the immune system. Nevertheless, the effectiveness of pyroptosis in tumor immunotherapy is impeded by critical factors such as the failure to address nuclear factor-κB (NF-κB) priming, insufficient inflammasome activation, and limited light and oxygen penetration. To confront these challenges, we constructed crystalline dendritic mesoporous gadolinium oxide (DM-Gd<sub>2</sub>O<sub>3</sub> nanoparticles) loaded with a peroxyoxalate-based chemiluminescence system and encapsulated by calcium carbonate (CaCO<sub>3</sub>) nanoparticles to form self-amplifying pyroptosis nanoinducers. Within the tumor microenvironment (TME), the release of pH-responsive calcium (Ca<sup>2+</sup>) and gadolinium ions (Gd<sup>3+</sup>) promotes the priming of NF-κB and disrupts lysosomal membrane phosphate groups, thereby inducing lysosomal rupture. Additionally, bis(3,4,6-trichloro-2-(pentyloxycarbonyl) phenyl) oxalate (CPPO) reacts with hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) to form a high-energy intermediate that emits light, exciting chlorin e6 (Ce6) to produce singlet oxygen. This process overcomes the limitations of light penetration and tumor hypoxia, synergizes with pyroptosis, and triggers a strong antitumor immune response <em>in vitro</em> and <em>in vivo</em>. This study introduces a novel approach to the design of self-amplifying pyroptosis nanoinducers for tumor immunotherapy.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114689"},"PeriodicalIF":11.5,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146134114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-05DOI: 10.1016/j.jconrel.2026.114692
Lubin Ning , Rui Xu , Chaoke Qin , Lei Sun , Liming Shao , Hongrui Zhang , Li Yan , Gengzhi Ren , Xiuying Sun , Hao Chang , Xiangdong Cheng , Fie Jia
The clinical utility of membrane-lytic peptides (MLPs) as cancer therapeutics is severely compromised by their inherent instability, rapid clearance, and non-specific toxicity, including hemolysis. We report a unimolecular nanoparticle platform, the Charge-Alternating Spherical MLP (CAS-MLP), engineered to overcome these barriers through a synergistic structural and chemical design. Structurally, MLPs are grafted as side chains onto a redox-responsive poly(disulfide) backbone, forming a bottlebrush architecture that enhances proteolytic stability and prolongs circulation. Chemically, the MLPs' lytic activity is temporarily neutralized using detachable charge-alternating (CA) reagents via maleamic anhydride-amine chemistry. This “smart” shielding minimizes hemolysis and off-target toxicity while also serving as a conjugation point for cancer-specific ligands, enabling precisely tuned targeting. This platform is designed for sequential intracellular activation: after ligand-mediated uptake, the acidic endosomal environment triggers CA reagent detachment, while the reductive cytosol degrades the poly(disulfide) backbone. This dual-stimuli-triggered disassembly selectively restores the MLP's lytic function inside the cancer cell. In vivo, the CAS-MLP platform demonstrates potent tumor growth suppression with negligible side effects. By leveraging the abundant lysine residues of MLPs, this approach provides a versatile and effective solution to key challenges in MLP-based therapy.
{"title":"Selective tumor lysis by charge-alternating spherical membrane-lytic peptide bottlebrushes via redox backbone degradation and pH-gated unmasking","authors":"Lubin Ning , Rui Xu , Chaoke Qin , Lei Sun , Liming Shao , Hongrui Zhang , Li Yan , Gengzhi Ren , Xiuying Sun , Hao Chang , Xiangdong Cheng , Fie Jia","doi":"10.1016/j.jconrel.2026.114692","DOIUrl":"10.1016/j.jconrel.2026.114692","url":null,"abstract":"<div><div>The clinical utility of membrane-lytic peptides (MLPs) as cancer therapeutics is severely compromised by their inherent instability, rapid clearance, and non-specific toxicity, including hemolysis. We report a unimolecular nanoparticle platform, the Charge-Alternating Spherical MLP (CAS-MLP), engineered to overcome these barriers through a synergistic structural and chemical design. Structurally, MLPs are grafted as side chains onto a redox-responsive poly(disulfide) backbone, forming a bottlebrush architecture that enhances proteolytic stability and prolongs circulation. Chemically, the MLPs' lytic activity is temporarily neutralized using detachable charge-alternating (CA) reagents <em>via</em> maleamic anhydride-amine chemistry. This “smart” shielding minimizes hemolysis and off-target toxicity while also serving as a conjugation point for cancer-specific ligands, enabling precisely tuned targeting. This platform is designed for sequential intracellular activation: after ligand-mediated uptake, the acidic endosomal environment triggers CA reagent detachment, while the reductive cytosol degrades the poly(disulfide) backbone. This dual-stimuli-triggered disassembly selectively restores the MLP's lytic function inside the cancer cell. <em>In vivo</em>, the CAS-MLP platform demonstrates potent tumor growth suppression with negligible side effects. By leveraging the abundant lysine residues of MLPs, this approach provides a versatile and effective solution to key challenges in MLP-based therapy.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114692"},"PeriodicalIF":11.5,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146122106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-05DOI: 10.1016/j.jconrel.2026.114688
Jiamin Li, Rongrong Li, Yan Zhou, Shengping Zheng, Jingjing Xu, Jingli Zhu, Yunqing Pang, Jing Wang
The treatment of diabetic periodontitis is significantly challenged by a pathological microenvironment characterized by hyperglycemia, proinflammatory cytokine storm, and excessive reactive oxygen species (ROS), with current therapeutic strategies offering limited efficacy and susceptibility to antibiotic resistance. Although liraglutide (LIRA) possesses multifaceted therapeutic potential, including glycemic control, anti-inflammation, antioxidation, and osteoprotection, its systemic administration fails to achieve effective local concentrations within periodontal tissues. To address this, we engineered an injectable carboxymethyl chitosan-oxidized dextran hydrogel (LIRA@CMCS-OD) via dynamic Schiff base bonds for localized LIRA delivery. This hydrogel exhibited excellent injectability, tissue adhesion, biocompatibility, and pH-responsive drug release kinetics. In vitro studies demonstrated that LIRA@CMCS-OD inhibited Porphyromonas gingivalis growth, effectively scavenged intracellular ROS in human periodontal ligament cells (hPDLCs), and robustly promoted hPDLCs osteogenic differentiation. In a diabetic periodontitis rat model, local application of LIRA@CMCS-OD significantly ameliorated gingival inflammation and tooth mobility, enhanced alveolar bone regeneration, and demonstrated favorable biosafety. By enabling sustained local drug release and orchestrating a synergistic “antibacterial action-antioxidation- osteogenic protection” mechanism, this LIRA-loaded injectable hydrogel presents a potent and safe therapeutic strategy for diabetic periodontitis.
{"title":"Injectable Schiff base-engineered hydrogel for spatiotemporal liraglutide delivery orchestrates diabetic periodontitis regression via multimodal microenvironment reprogramming","authors":"Jiamin Li, Rongrong Li, Yan Zhou, Shengping Zheng, Jingjing Xu, Jingli Zhu, Yunqing Pang, Jing Wang","doi":"10.1016/j.jconrel.2026.114688","DOIUrl":"https://doi.org/10.1016/j.jconrel.2026.114688","url":null,"abstract":"The treatment of diabetic periodontitis is significantly challenged by a pathological microenvironment characterized by hyperglycemia, proinflammatory cytokine storm, and excessive reactive oxygen species (ROS), with current therapeutic strategies offering limited efficacy and susceptibility to antibiotic resistance. Although liraglutide (LIRA) possesses multifaceted therapeutic potential, including glycemic control, anti-inflammation, antioxidation, and osteoprotection, its systemic administration fails to achieve effective local concentrations within periodontal tissues. To address this, we engineered an injectable carboxymethyl chitosan-oxidized dextran hydrogel (LIRA@CMCS-OD) via dynamic Schiff base bonds for localized LIRA delivery. This hydrogel exhibited excellent injectability, tissue adhesion, biocompatibility, and pH-responsive drug release kinetics. In vitro studies demonstrated that LIRA@CMCS-OD inhibited <em>Porphyromonas gingivalis</em> growth, effectively scavenged intracellular ROS in human periodontal ligament cells (hPDLCs), and robustly promoted hPDLCs osteogenic differentiation. In a diabetic periodontitis rat model, local application of LIRA@CMCS-OD significantly ameliorated gingival inflammation and tooth mobility, enhanced alveolar bone regeneration, and demonstrated favorable biosafety. By enabling sustained local drug release and orchestrating a synergistic “antibacterial action-antioxidation- osteogenic protection” mechanism, this LIRA-loaded injectable hydrogel presents a potent and safe therapeutic strategy for diabetic periodontitis.","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"17 1","pages":""},"PeriodicalIF":10.8,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146122107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-04DOI: 10.1016/j.jconrel.2026.114673
Jingjuan Zhang , Yongzheng Li , Huiyuan Jin , Peizhen Yang , Huan Min , Jian Song , Yingqiu Qi
Proteolysis targeting chimeras (PROTACs) are catalytic degraders that eliminate pathogenic proteins via the ubiquitin-proteasome system (UPS). Building on this mechanism, nano-engineered PROTACs (Nano-PROTACs) integrate PROTACs with rationally designed nanomaterials to create an emerging therapeutic platform for cancer. This integrative approach preserves the core capability of PROTACs to precisely degrade pathogenic proteins through the UPS, and also confers multiple therapeutic advantages including enhanced tissue targeting, improved membrane permeability, and controlled drug release, thereby significantly improving cancer therapeutic efficacy while effectively reducing systemic toxicity. This review provides a comprehensive overview of recent advances in Nano-PROTACs for cancer therapy, with a particular focus on the design strategies enabled by nanomaterial-based delivery systems, along with the applications in monotherapy and synergistic therapies. In addition, the therapeutic advantages and existing challenges of Nano-PROTACs are critically discussed, while delineating their potential future clinical applications, providing critical insights to the understanding of this emerging technology and offering novel perspectives for future development of precision therapeutics.
{"title":"New-generation advanced Nano-PROTACs as potential therapeutic agents in cancer therapy","authors":"Jingjuan Zhang , Yongzheng Li , Huiyuan Jin , Peizhen Yang , Huan Min , Jian Song , Yingqiu Qi","doi":"10.1016/j.jconrel.2026.114673","DOIUrl":"10.1016/j.jconrel.2026.114673","url":null,"abstract":"<div><div>Proteolysis targeting chimeras (PROTACs) are catalytic degraders that eliminate pathogenic proteins via the ubiquitin-proteasome system (UPS). Building on this mechanism, nano-engineered PROTACs (Nano-PROTACs) integrate PROTACs with rationally designed nanomaterials to create an emerging therapeutic platform for cancer. This integrative approach preserves the core capability of PROTACs to precisely degrade pathogenic proteins through the UPS, and also confers multiple therapeutic advantages including enhanced tissue targeting, improved membrane permeability, and controlled drug release, thereby significantly improving cancer therapeutic efficacy while effectively reducing systemic toxicity. This review provides a comprehensive overview of recent advances in Nano-PROTACs for cancer therapy, with a particular focus on the design strategies enabled by nanomaterial-based delivery systems, along with the applications in monotherapy and synergistic therapies. In addition, the therapeutic advantages and existing challenges of Nano-PROTACs are critically discussed, while delineating their potential future clinical applications, providing critical insights to the understanding of this emerging technology and offering novel perspectives for future development of precision therapeutics.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114673"},"PeriodicalIF":11.5,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146122130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-04DOI: 10.1016/j.jconrel.2026.114687
Xin Huang , Yan-Yun Sun , Yi-Ren Qin , Hong Chen , Ting-Ting Pan , Song-Song Zhao , Qian Cai , Xiao-Shuo Zhang , Xiao-Dong Nie , Lei Feng , Hua Hu , Yong Tang , Pei-Zhuo Zhang , Zhi-Yuan Zhong , Jie Li , Li Lu , Feng-Hua Meng , Quan-Hong Ma
Toll-like receptor 9 (TLR9), expressed in both microglia and neurons of the CNS, represents a promising therapeutic target for Alzheimer's disease (AD). While either microglial or neuronal TLR9 activation exerts neuroprotective effects that ameliorate AD pathology and preserve cognitive function, CpG oligodeoxynucleotides (ODNs), the synthetic agonists, cannot cross the blood-brain barrier (BBB). To overcome this, we developed tNCpG, an apolipoprotein E (ApoE)-functionalized polymersome nanocarrier for brain-targeted delivery of CpG ODNs. APP/PS1 transgenic mice, which overexpress human mutant APP/PS1 and are widely used in AD mouse models for preclinical studies, were administered tNCpG intravenously biweekly for 3 months, starting at 4 months of age. tNCpG achieved efficient brain delivery while specifically targeting microglia and neurons. tNCpG treatment enhanced microglial recruitment to and phagocytosis of Aβ plaques, suppressed Aβ production while promoting its degradation, and improved BBB integrity and Aβ efflux. Collectively, these effects significantly reduced cerebral Aβ burden, neuroinflammation, and neurodegeneration, leading to the rescue of cognitive deficits. Our study establishes targeted TLR9 activation via tNCpG as a disease-modifying therapeutic strategy for AD.
{"title":"ApoE-directed CpG nano-immunoadjuvant ameliorates Alzheimer's-like pathology in mice","authors":"Xin Huang , Yan-Yun Sun , Yi-Ren Qin , Hong Chen , Ting-Ting Pan , Song-Song Zhao , Qian Cai , Xiao-Shuo Zhang , Xiao-Dong Nie , Lei Feng , Hua Hu , Yong Tang , Pei-Zhuo Zhang , Zhi-Yuan Zhong , Jie Li , Li Lu , Feng-Hua Meng , Quan-Hong Ma","doi":"10.1016/j.jconrel.2026.114687","DOIUrl":"10.1016/j.jconrel.2026.114687","url":null,"abstract":"<div><div>Toll-like receptor 9 (TLR9), expressed in both microglia and neurons of the CNS, represents a promising therapeutic target for Alzheimer's disease (AD). While either microglial or neuronal TLR9 activation exerts neuroprotective effects that ameliorate AD pathology and preserve cognitive function, CpG oligodeoxynucleotides (ODNs), the synthetic agonists, cannot cross the blood-brain barrier (BBB). To overcome this, we developed tNCpG, an apolipoprotein E (ApoE)-functionalized polymersome nanocarrier for brain-targeted delivery of CpG ODNs. APP/PS1 transgenic mice, which overexpress human mutant APP/PS1 and are widely used in AD mouse models for preclinical studies, were administered tNCpG intravenously biweekly for 3 months, starting at 4 months of age. tNCpG achieved efficient brain delivery while specifically targeting microglia and neurons. tNCpG treatment enhanced microglial recruitment to and phagocytosis of Aβ plaques, suppressed Aβ production while promoting its degradation, and improved BBB integrity and Aβ efflux. Collectively, these effects significantly reduced cerebral Aβ burden, neuroinflammation, and neurodegeneration, leading to the rescue of cognitive deficits. Our study establishes targeted TLR9 activation via tNCpG as a disease-modifying therapeutic strategy for AD.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114687"},"PeriodicalIF":11.5,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}